AUTHORS
Vivian Irizarry Gatell, MD, Rawan Faramand, MD2, Temitope Oloyede, MPH3, Soyoung Kim, PhD4, Jinalben Patel, MPH, BDS5, Andrew Peterson, MS6, Sairah Ahmed, MD7, Poorva Bindal, MD8, Shatha Farhan, MD9, Betty Hamilton, MD10, Annie Im, MD11, Reena Jayani-Kosarzycki, MD, MSCI12, Christine Phillips, MD13, Seth Rotz, MD14, Bipin Savani, MD15, Hélène M Schoemans, MD, PhD16, Michelle L. Schoettler, MD17, Mohamed Sorror, MD, MS18, Cameron J. Turtle, MBBS, PhD19, Rachel Phelan, MD, MPH20, Amy Moskop, MS MD21, Mithun Shah, MD, PhD22
AFFILIATIONS
1 UT Southwestern Medical Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
8 UMass Memorial Medical Center, Worcester, Massachusetts, United States
9 Henry Ford Health System Stem Cell Transplant & Cellular Therapy Program, Detroit, Michigan, United States
10 Cleveland Clinic Cancer Institute, Cleveland, Ohio, United States
11 University of Pittsburgh/UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
12 Vanderbilt University Medical Center, Nashville, Tennessee, United States
13 Cincinnati Children's Hospital, Cincinnati, Ohio, United States
14 Cleveland Clinic, Cleveland, Ohio, United States
15 Vanderbilt University Medical Center, Nashville, Tennessee, United States
16 University Hospitals Leuven, Leuven, Belgium, University of Leuven, Leuven, Belgium
17 Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States
18 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
19 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Royal North Shore Hospital, St. Leonards, Australia, University of Sydney, Sydney, Australia
20 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
21 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
22 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background. Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of adults with non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and B acute lymphoblastic leukemia (B-ALL) Second primary malignancies (SPM), including second hematologic malignancies (SHM), are known complications of cytotoxic therapies including stem cell transplantation (SCT), but their incidence, risk factors, and impact of SPM/SHM on survival after CAR-T are not well defined.
Methods. This retrospective study used CIBMTR data and included NHL, MM, and B-ALL patients who underwent CAR-T therapy between 2017 and 2024. Descriptive statistics summarized categorical variables as counts and percentages and continuous variables as medians with ranges. Patient-, disease-, and CAR-T-related factors were compared between groups using chi-square tests for categorical variables and Kruskal-Wallis tests for continuous variables. Using landmark analysis, cumulative incidence of SPM/SHM was calculated from day +120 to development of the first SPM/SHM among those who were alive, in remission, and had not developed SPM/SHM by day +120. Overall survival (OS) was estimated using the Kaplan-Meier method with log-rank. Cox proportional hazards regression models evaluated the impact of SPM/SHM as time-dependent variables. Cause-specific hazard models were used to assess risk factors for SPM/SHM. Proportional hazards assumptions were assessed, time-dependent variables were added if assumptions were violated, and a stepwise model-building approach retained variables with a P-value <5% in the final model. Interactions and center effects were tested.
Results. Among 10,240 cases, 8193 had NHL, 1007 had MM, and 1040 had B-ALL. Median age at CAR-T infusion was 62.7 years (range, 0-91). Most were male (64%), White (76%) and non-Hispanic/Latino (75%). 2898 (28%) patients had undergone SCT [autologous - 2490 (24%); allogeneic - 327 (3%); both 41 (1.4%); and information unknown (40, 1.4%)]. Most common CAR-T products in the cohort were Yescarta (58%), Kymriah (22%), Abecma (8%) and Tecartus (8%). Solid or heme malignancies were documented before CAR-T in 1571 (15%) cases.
After a median follow-up of 23.4 months (range 0.5-76), 586 (6%) SPM were documented. Of these, 327 (55.8%) were non-heme SPM, 259 (44.2%) were SHM. Incidence of SPM in NHL, ALL, and MM was 514 (6%), 11 (1%), and 61 (6%), respectively.
The five most common SPM were MDS (n=173,30%), squamous cell carcinoma (n=121,21%), basal cell carcinoma (n=66,11%), GU malignancies (n=34,6%) and AML (n=33,6%). Only 7 (0.09%) T-cell malignancies were documented. Time from CAR-T (median, range) to first SPM, SHM, therapy-related myeloid neoplasm, and T-cell malignancy was 11.2 (0.1-76), 11.8 (0.1-76), 14.8 (1.1-66.1), and 15.2 (0.9-37.1) months, respectively.
Cumulative incidence (%, 95% CI) of SPM among those who were alive, in remission, and had no SPM by day +120 (N=6263, NHL: 4942, ALL: 740, MM: 581) at 12-, and 24-month was 3.4 (3-3.9), and 7.1 (6.3-7.8), respectively. The cumulative incidence of SHM was 1.3 (1-1.6) and 3.4 (2.8-3.9), respectively. Among those alive at 6 months, 1-year OS (%) with no SPM, non-heme SPM, and SHM was 84.2% vs. 82% vs. 62.2% (P<0.001). Similarly, 2-year survival among no SPM, non-heme SPM, and SHM was 67.4% vs. 58.2% vs. 28.4%, respectively (P<0.001).
Given the relative infrequency of SPM/SHM in B-ALL, multivariable analysis was limited to NHL and MM. Older age, male gender, prior SCT, white race, and development of grade ≥2 immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with SPM development (P <0.001); whereas older age and prior SCT were associated with higher risk of SHM (P <0.001). Finally, the development of SPM (HR, 2.27; 95% CI 1.99-2.59; P <0.001).) or SHM (HR, 4.3; 95% CI 3.6-5.13, P <0.001) were independently associated with inferior survival.
Conclusions. SPM and SHM in this heavily pretreated cohort represent uncommon but clinically meaningful complications in CAR-T recipients with cumulative incidence continuing to increase beyond the first year. Older age, male gender, prior SCT, white race, and grade ≥2 ICANS were associated with an increased risk of SPM. Importantly, SPM and SHM were independently associated with inferior survival underscoring the need for close long-term follow-up.
DISCLOSURES
Vivian Irizarry Gatell, MD: No relevant conflicts of interest to declare.